“ENV-294, a once-daily pill for atopic dermatitis, reduced eczema severity by an average of 85% after 42 days in a Phase 1b study, with no serious side effects reported.”

Quartz · Sep 22 · Enveda raises $311M at $2B valuation to advance AI-discovered drugs

“The Boulder, Colorado company deploys an AI platform called PRISM to surface therapeutic compounds derived from plants and microbes. Rather than designing molecules from scratch, the system predicts molecular structures from mass spectrometry data, guides laboratory experiments, and ranks candidates by therapeutic potential.”

Quartz · Sep 22 · Enveda raises $311M at $2B valuation to advance AI-discovered drugs